Loxapine SuccinateCAS# 27833-64-3 |
- Atorvastatin Calcium
Catalog No.:BCC2319
CAS No.:134523-03-8
- Pitavastatin Calcium
Catalog No.:BCC3842
CAS No.:147526-32-7
- Pravastatin sodium
Catalog No.:BCC2321
CAS No.:81131-70-6
- Fluvastatin
Catalog No.:BCC1579
CAS No.:93957-54-1
- Fluvastatin Sodium
Catalog No.:BCC2317
CAS No.:93957-55-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 27833-64-3 | SDF | Download SDF |
| PubChem ID | 71399 | Appearance | Powder |
| Formula | C22H24ClN3O5 | M.Wt | 445.9 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 100 mg/mL (224.27 mM; Need ultrasonic) | ||
| Chemical Name | butanedioic acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine | ||
| SMILES | CN1CCN(CC1)C2=Nc3ccccc3Oc4ccc(Cl)cc24.OC(=O)CCC(O)=O | ||
| Standard InChIKey | YQZBAXDVDZTKEQ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H18ClN3O.C4H6O4/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18;5-3(6)1-2-4(7)8/h2-7,12H,8-11H2,1H3;1-2H2,(H,5,6)(H,7,8) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Loxapine Succinate Dilution Calculator
Loxapine Succinate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2427 mL | 11.2133 mL | 22.4266 mL | 44.8531 mL | 56.0664 mL |
| 5 mM | 0.4485 mL | 2.2427 mL | 4.4853 mL | 8.9706 mL | 11.2133 mL |
| 10 mM | 0.2243 mL | 1.1213 mL | 2.2427 mL | 4.4853 mL | 5.6066 mL |
| 50 mM | 0.0449 mL | 0.2243 mL | 0.4485 mL | 0.8971 mL | 1.1213 mL |
| 100 mM | 0.0224 mL | 0.1121 mL | 0.2243 mL | 0.4485 mL | 0.5607 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent.
- Serratenediol diacetate
Catalog No.:BCN5173
CAS No.:27832-84-4
- Sunset yellow
Catalog No.:BCN2222
CAS No.:2783-94-0
- UDP disodium salt
Catalog No.:BCC7570
CAS No.:27821-45-0
- Loroquine
Catalog No.:BCN2008
CAS No.:27792-82-1
- Uncarinic acid E
Catalog No.:BCN6774
CAS No.:277751-61-8
- 9-Angeloylretronecine N-oxide
Catalog No.:BCN2037
CAS No.:27773-86-0
- Ervamycine
Catalog No.:BCN5172
CAS No.:27773-39-3
- 5-Hydroxy-1-methoxyxanthone
Catalog No.:BCN6575
CAS No.:27770-13-4
- Pahutoxin
Catalog No.:BCN1811
CAS No.:27742-14-9
- Geniposidic acid
Catalog No.:BCN5171
CAS No.:27741-01-1
- Erysotrine
Catalog No.:BCN5170
CAS No.:27740-43-8
- Scutellarin
Catalog No.:BCN5902
CAS No.:27740-01-8
- Macrophylline
Catalog No.:BCN1987
CAS No.:27841-97-0
- Nicergoline
Catalog No.:BCC5214
CAS No.:27848-84-6
- Lamiide
Catalog No.:BCN4656
CAS No.:27856-54-8
- NH125
Catalog No.:BCC4001
CAS No.:278603-08-0
- Croceic acid
Catalog No.:BCN2372
CAS No.:27876-94-4
- GW4064
Catalog No.:BCC4500
CAS No.:278779-30-9
- Bis(4-bromophenyl)acetylene
Catalog No.:BCC8882
CAS No.:2789-89-1
- H-Lys(Z)-OMe.HCl
Catalog No.:BCC2988
CAS No.:27894-50-4
- H-Glu(OBzl)-OBzl.TosOH
Catalog No.:BCC2928
CAS No.:2791-84-6
- 14-Deoxy-epsilon-caesalpin
Catalog No.:BCN7254
CAS No.:279683-46-4
- 2-Amino-3-chloro-1,4-naphthoquinone
Catalog No.:BCC8525
CAS No.:2797-51-5
- 1,6-Dibromopyrene
Catalog No.:BCC8428
CAS No.:27973-29-1
Loxapine succinate as initial treatment of hostile and aggressive schizophrenic criminal offenders.[Pubmed:7130427]
J Clin Pharmacol. 1982 Aug-Sep;22(8-9):366-70.
The efficacy and safety of loxapine were evaluated in 18 acutely ill schizophrenic criminal offenders in the Essex County Jail. The offender patients were treated for three days with intramuscular loxapine (25 mg three or four times a day), followed by seven days of oral concentrate (up to 150 mg/day in three or four divided doses). Psychiatric status was determined with the Brief Psychiatric Rating and the Clinical Global impression scales at the time of admission, after 8, 24, 48, and 72 hours, amd on days 7 and 10 of medication. Three patients did not complete treatment: one was released on bail after 24 hours of therapy, and the other two had adverse reactions (tongue swelling and muscle spasms, each in one patient) which required cessation of treatment. Statistically significant improvement in both rating scale results was evident as early as 8 hours after treatment began. By day 10, all Brief Psychiatric Rating Scale items and factors and the Clinical Global impression results were statistically improved over baseline measurements. At the end of the study, 87 per cent (13/15) of the patients were well enough to cooperate with their attorneys and understand the procedures of the court. Adverse effects (generally extrapyramidal) appeared in four of 18 patients during parenteral administration and in two of 15 patients during oral therapy.
A complementary experimental and computational study of loxapine succinate and its monohydrate.[Pubmed:24192171]
Acta Crystallogr C. 2013 Nov;69(Pt 11):1273-8.
The crystal structures of Loxapine Succinate [systematic name: 4-(2-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-1-methylpiperazin-1-ium 3-carboxypropanoate], C18H19ClN3O(+).C4H5O4(-), and Loxapine Succinate monohydrate {systematic name: bis[4-(2-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-1-methylpiperazin-1-ium] succinate succinic acid dihydrate}, 2C18H19ClN3O(+).C4H4O4(2-).C4H6O4.2H2O, have been determined using X-ray powder diffraction and single-crystal X-ray diffraction, respectively. Fixed cell geometry optimization calculations using density functional theory confirmed that the global optimum powder diffraction derived structure also matches an energy minimum structure. The energy calculations proved to be an effective tool in locating the positions of the H atoms reliably and verifying the salt configuration of the structure determined from powder data. Crystal packing analysis of these structures revealed that the Loxapine Succinate structure is based on chains of protonated loxapine molecules while the monohydrate contains dispersion stabilized centrosymmetric dimers. Incorporation of water molecules within the crystal lattice significantly alters the molecular packing and protonation state of the succinic acid.
[Clinical trial of loxapine succinate in the treatment of 30 cases of psychotic states].[Pubmed:6357022]
Ann Med Psychol (Paris). 1983 Mar;141(3):309-22.
An open clinical study of Loxapine Succinate was developed on 30 hospitalized psychiatric patients in order to confirm its antipsychotic properties and its originality opposite the other major neuroleptics. Dosages ranged from 100 to 200 mg per day in 12 cases (40%), and more than 200 mg in serious psychosis or unamenable to therapeutic for which inferior dosages were inefficacious (11 cases). 56,7% of favourable results have been obtained, with a fair improvement of whole symptoms, paranoid schizophrenic attack and acute delusions. Tolerance was remarkable: no neuro-vegetative manifestation was reported. The considerable sedative effect of loxapine had involved moderate and no invalidating drowsiness in 23% of cases. The extra-pyramidal occurring symptoms disappeared within 2 or 3 days. So Loxapine Succinate in proving to be a major first intention neuroleptic, suiting a considerable antipsychotic efficacy to a good tolerance, allowing new perspectives in the therapeutic and the approach of psychotic patients.
